Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 1988 Oct;80(10):1133–1135.

Emergence of Imipenem-Resistant Pseudomonas aeruginosa During Treatment of Intra-abdominal Infection in a Patient With Ovarian Carcinoma

Eddie H Sze, Newton G Osborne, Mark D Adelson, Paul Granato
PMCID: PMC2625865  PMID: 3150461

Abstract

A 59-year-old woman was admitted to the hospital with ovarian carcinoma. After cytoreductive surgery, the patient developed intra-abdominal sepsis. After 17 days of intravenous imipenem, the patient's sputum culture grew imipenem-resistant Pseudomonas aeruginosa. On the 21st day of treatment with imipenem, her peritoneal culture also grew imipenem-resistant Pseudomonas aeruginosa.

Full text

PDF
1133

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acar J. F. Therapy for lower respiratory tract infections with imipenem/cilastatin: a review of worldwide experience. Rev Infect Dis. 1985 Jul-Aug;7 (Suppl 3):S513–S517. doi: 10.1093/clinids/7.supplement_3.s513. [DOI] [PubMed] [Google Scholar]
  2. Angus B. L., Carey A. M., Caron D. A., Kropinski A. M., Hancock R. E. Outer membrane permeability in Pseudomonas aeruginosa: comparison of a wild-type with an antibiotic-supersusceptible mutant. Antimicrob Agents Chemother. 1982 Feb;21(2):299–309. doi: 10.1128/aac.21.2.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Aronoff S. C., Shlaes D. M. Factors that influence the evolution of beta-lactam resistance in beta-lactamase-inducible strains of Enterobacter cloacae and Pseudomonas aeruginosa. J Infect Dis. 1987 May;155(5):936–941. doi: 10.1093/infdis/155.5.936. [DOI] [PubMed] [Google Scholar]
  4. Bell S. M., Pham J. N., Lanzarone J. Y. Mutation of Pseudomonas aeruginosa to piperacillin resistance mediated by beta-lactamase production. J Antimicrob Chemother. 1985 Jun;15(6):665–670. doi: 10.1093/jac/15.6.665. [DOI] [PubMed] [Google Scholar]
  5. Bryan L. E., Kwan S., Godfrey A. J. Resistance of Pseudomonas aeruginosa mutants with altered control of chromosomal beta-lactamase to piperacillin, ceftazidime, and cefsulodin. Antimicrob Agents Chemother. 1984 Mar;25(3):382–384. doi: 10.1128/aac.25.3.382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Büscher K. H., Cullmann W., Dick W., Opferkuch W. Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein. Antimicrob Agents Chemother. 1987 May;31(5):703–708. doi: 10.1128/aac.31.5.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Büscher K. H., Cullmann W., Dick W., Wendt S., Opferkuch W. Imipenem resistance in Pseudomonas aeruginosa is due to diminished expression of outer membrane proteins. J Infect Dis. 1987 Oct;156(4):681–684. doi: 10.1093/infdis/156.4.681. [DOI] [PubMed] [Google Scholar]
  8. Fan W., del Busto R., Love M., Markowitz N., Cendrowski C., Cardenas J., Quinn E., Saravolatz L. Imipenem-cilastatin in the treatment of methicillin-sensitive and methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother. 1986 Jan;29(1):26–29. doi: 10.1128/aac.29.1.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Freimer E. H., Donabedian H., Raeder R., Ribner B. S. Empirical use of imipenem as the sole antibiotic in the treatment of serious infections. J Antimicrob Chemother. 1985 Oct;16(4):499–507. doi: 10.1093/jac/16.4.499. [DOI] [PubMed] [Google Scholar]
  10. Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections. Report from a Scandinavian Study Group. Lancet. 1984 Apr 21;1(8382):868–871. [PubMed] [Google Scholar]
  11. Knothe H., Antal M., Krcméry V. Imipenem and ceftazidime resistance in Pseudomonas aeruginosa and Klebsiella pneumoniae. J Antimicrob Chemother. 1987 Jan;19(1):136–138. doi: 10.1093/jac/19.1.136. [DOI] [PubMed] [Google Scholar]
  12. Pedersen S. S., Pressler T., Høiby N., Bentzon M. W., Koch C. Imipenem/cilastatin treatment of multiresistant Pseudomonas aeruginosa lung infection in cystic fibrosis. J Antimicrob Chemother. 1985 Nov;16(5):629–635. doi: 10.1093/jac/16.5.629. [DOI] [PubMed] [Google Scholar]
  13. Quinn J. P., Dudek E. J., DiVincenzo C. A., Lucks D. A., Lerner S. A. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis. 1986 Aug;154(2):289–294. doi: 10.1093/infdis/154.2.289. [DOI] [PubMed] [Google Scholar]
  14. Saino Y., Kobayashi F., Inoue M., Mitsuhashi S. Purification and properties of inducible penicillin beta-lactamase isolated from Pseudomonas maltophilia. Antimicrob Agents Chemother. 1982 Oct;22(4):564–570. doi: 10.1128/aac.22.4.564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Vurma-Rapp U., Kayser F. H., Barberis-Maino L. Antibacterial properties of imipenem with special reference to the activity against methicillin-resistant staphylococci, cefotaxime-resistant Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 1986 Dec;18 (Suppl E):27–33. doi: 10.1093/jac/18.supplement_e.27. [DOI] [PubMed] [Google Scholar]
  16. Winston D. J., McGrattan M. A., Busuttil R. W. Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections. Antimicrob Agents Chemother. 1984 Nov;26(5):673–677. doi: 10.1128/aac.26.5.673. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Witte J. L., Sapico F. L., Canawati H. N. In vitro susceptibility of methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains to N-formimidoyl thienamycin. Antimicrob Agents Chemother. 1982 Nov;22(5):906–908. doi: 10.1128/aac.22.5.906. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES